Literature DB >> 3493837

Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia.

A H Mudde, H van den Berg, P G Boshuis, F C Breedveld, H M Markusse, P M Kluin, O L Bijvoet, S E Papapoulos.   

Abstract

A patient with long-standing rheumatoid arthritis developed hypercalcemia (3.13 mmol/l) and was subsequently found to have a B-cell lymphoma (centroblastic type). The hypercalcemia was associated with high circulating concentrations of 1,25-dihydroxyvitamin D (235 pmol/l) and both abnormalities were corrected with treatment. A lymph node was excised before treatment and was incubated in vitro with either labeled or unlabeled 25-hydroxyvitamin D3. After purification of the extract and chromatography on three different HPLC systems, material comigrating with authentic 1,25-dihydroxyvitamin D3 was identified. This was shown to bind to a specific chick intestinal cytosol receptor and to dilute in parallel with synthetic 1,25-dihydroxyvitamin D3 in the receptor binding assay. In conclusion, hypercalcemia in malignant B-cell lymphoma can be due to extrarenal production of 1,25-dihydroxyvitamin D by lymphomatous tissue.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493837     DOI: 10.1002/1097-0142(19870501)59:9<1543::aid-cncr2820590902>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Intermittent hypercalcaemia and vitamin D sensitivity in Hodgkin's disease.

Authors:  R Karmali; S Barker; M Hewison; L Fraher; D R Katz; J L O'Riordan
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

Review 2.  1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: two case reports.

Authors:  J P Devogelaer; M Lambert; B Boland; C Godfraind; H Noel; C Nagant de Deuxchaisnes
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide.

Authors:  T Michigami; M Nomizu; Y Yamada; C Dunstan; P J Williams; G R Munday; T Yoneda
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 4.  Calcium and vitamin D metabolism in granulomatous diseases.

Authors:  M Fuss; T Pepersack; C Gillet; R Karmali; J Corvilain
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

Review 5.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

6.  Elevated serum parathyroid hormone related protein and 1,25-dihydroxycholecalciferol in hypercalcaemia associated with adult T-cell leukaemia-lymphoma.

Authors:  S R Johnston; P J Hammond
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

7.  Hypercalcemia in Lung Cancer due to Simultaneously Elevated PTHrP and Ectopic Calcitriol Production: First Case Report.

Authors:  Saed Nemr; Sunitha Alluri; Dhivya Sundaramurthy; Daniel Landry; Gregory Braden
Journal:  Case Rep Oncol Med       Date:  2017-07-02

8.  Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.

Authors:  Duncan M Gascoyne; Linden Lyne; Hayley Spearman; Francesca M Buffa; Elizabeth J Soilleux; Alison H Banham
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

Review 9.  Vitamin D Toxicity-A Clinical Perspective.

Authors:  Ewa Marcinowska-Suchowierska; Małgorzata Kupisz-Urbańska; Jacek Łukaszkiewicz; Paweł Płudowski; Glenville Jones
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-20       Impact factor: 5.555

10.  Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report.

Authors:  Maarten Haemels; Thierry Delaunoit; Koen Van Laere; Eric Van Cutsem; Chris Verslype; Christophe M Deroose
Journal:  BMC Gastroenterol       Date:  2020-10-02       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.